Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
148-0287-A-4.2mM-cartridge · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Trial part 1 | EXPERIMENTAL | - |
| Trial part 2, treatment A | EXPERIMENTAL | - |
| Trial part 2, treatment B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 148-0287-A-4.2mM-cartridge | DRUG | In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously. |
| placebo | DRUG | In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously. |
| insulin glargine | DRUG | In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B. |
| sodium chloride 0.9% w/v | DRUG | In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B. |
Inclusion Criteria: * TRIAL PART 1 (HEALTHY SUBJECTS): * Healthy male subject * Age 18-55 years (both inclusive) * Body mass index 18.0-28.0 kg/m\^2 (both inclusive) * TRIAL PART 2 (SUBJECTS WITH TYPE 1 DIABETES): * Healthy male subject (with the exception of conditions associated with diabetes mel...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
148-0287-A-4.2mM-cartridge is an investigational small molecule being developed for diabetes. It is currently in Phase 1 clinical development, meaning it has not been approved and is still being studied for safety and tolerability in humans.
148-0287-A-4.2mM-cartridge is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO.
148-0287-A-4.2mM-cartridge is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
148-0287-A-4.2mM-cartridge has one completed Phase 1 trial, registered as NCT01730014. The trial investigated safety, tolerability, distribution, and activity in healthy subjects and subjects with type 1 diabetes. It enrolled 70 male participants in Germany.
Yes, 148-0287-A-4.2mM-cartridge is the same as NNC0148-0000-0287. The clinical trial NCT01730014 refers to the drug as NNC0148-0000-0287, which is the active ingredient or compound name, while 148-0287-A-4.2mM-cartridge is the formulation name.